Mount Yale Investment Advisors’s Prometheus Biosciences, Inc. Common Stock RXDX Stock Holding History

Mount Yale Investment Advisors’s Portfolio RXDX Stock Details RXDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-2,266	Closed	-$243K	–	520
2023 Q1	$243K	Sell	2,266 -17	-0.7%	-$1.96K	0.03%	427
2022 Q4	$251K	Buy	+2,283	New	+$148K	0.03%	389

Other funds holding RXDX

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

FCA

FinTrust Capital Advisors Greenville, South Carolina $591M AUM 26.89% 1-Year Est. Return

Mount Yale Investment Advisors's RXDX Position: Q2 2023 in Review

Mount Yale Investment Advisors sold out of Prometheus Biosciences, Inc. Common Stock (RXDX) in Q2 2023, closing a stake of 2,266 shares — an estimated $243K sold.

Mount Yale Investment Advisors first reported a position in RXDX in Q4 2022 and held it in 2 quarters. The position peaked at $251K in Q4 2022. 2 funds tracked by Wall St. Rank hold RXDX as of Q2 2023.

Mount Yale Investment Advisors reported no remaining Prometheus Biosciences, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Mount Yale Investment Advisors sold 2,266 Prometheus Biosciences, Inc. Common Stock shares in Q2 2023, an estimated $243K.
Mount Yale Investment Advisors first reported a position in Prometheus Biosciences, Inc. Common Stock in Q4 2022 and held it in 2 quarters.
Mount Yale Investment Advisors's Prometheus Biosciences, Inc. Common Stock position peaked at $251K in Q4 2022.
2 funds tracked by Wall St. Rank held Prometheus Biosciences, Inc. Common Stock as of Q2 2023.

Based on Mount Yale Investment Advisors's 13F filing for Q2 2023, filed 14 Aug 2023.